.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
UBS
Queensland Health
Chinese Patent Office
Moodys
Covington
Boehringer Ingelheim
Merck
Citi
Dow

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Try a Free Trial

« Back to Dashboard

Details for Patent: ➤ Try a Free Trial

Title: Methods for treating disorders using descarboethoxyloratadine
Abstract:Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Inventor(s): Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA)
Assignee: Sepracor Inc. (Marlborough, MA) University of Massachusetts (Boston, MA)
Filing Date:Jan 13, 1997
Application Number:08/783,393
Claims:1. A method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

3. The method of claim 1 wherein said human has a higher than normal propensity for or incidence of cancer.

4. The method of claim 1, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

5. The method of claim 1 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.

6. The method of claim 5 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.

7. The method of claim 1 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Colorcon
Teva
Boehringer Ingelheim
Merck
Fuji
Covington
QuintilesIMS
Chinese Patent Office
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot